Optain

Name: Optain
Brand: Optain

Optain is a combined medical device, software, and clinical services platform for retinal screening that captures non-mydriatic retinal images, returns clinical reports via teleophthalmology or AI (outside the US), and integrates results into EHRs and quality dashboards.

Est 2019|Raised $37M

LinkedIn 932|Web traffic 2K|FTEs 20

Published Aug 18, 2026

01Common complaints

1) An organization requires autonomous AI in the US immediately - Public materials indicate automated disease detection software is not available for sale in the US. If autonomous, instant results are a procurement requirement, evaluate autonomous AI vendors. 2) An organization needs to purchase a camera outright in the US with clear list pricing - The vendor’s camera documentation indicates the Resolve camera is not for sale in the US and no public pricing was found. 3) An organization has minimal EHR integration bandwidth - The solution emphasizes EHR order/results workflows. If there is no capacity for interface work, a simpler standalone approach may be faster to deploy, though less integrated. 4) An organization’s bottleneck is downstream ophthalmology capacity - Screening will increase detection; without timely follow-up care the program may create operational risk. 5) Budget-constrained small practices - Smaller practices may prefer lower-cost cameras or shared screening models rather than an enterprise deployment requiring integration and program ops.

Deal disqualifiers

Requirement for autonomous AI in the US at present (vendor materials indicate automated detection is not sold in the US)
Requirement for public SOC 2/ISO documentation prior to engagement
Lack of capacity to operationalize referrals and follow-up care

Limitations explicitly stated or strongly implied in sources

Automated disease detection software is not for sale in the US (per Series A press materials)
The Resolve camera is not available for sale in the US (per camera documentation)

Roadmap / future capabilities

The vendor promotes broader oculomics capabilities and cardiovascular risk screening in some materials, but US commercialization appears constrained and public timelines are not provided.

Integration constraints

The vendor claims integration with major EHRs, but no exhaustive supported EHR list or interface specifications were publicly available in the reviewed materials.

Compliance/documentation gaps

No public SOC 2/ISO/HIPAA attestation or trust center pages were located in the reviewed sources.

02Why they buy

Unique selling points supported by public evidence

Acquisition of EyePACS provides a teleophthalmology reading network and vendor-reported volumes that could support scaling reading operations.
Emphasis on workflow integration: simplified capture, short training times claimed by the vendor, and rapid reporting to the EHR via teleophthalmology reads.

Claims that need validation

Statements that quality measure scores improve and that reimbursements increase are plausible but not quantified publicly. Buyers should request before/after quality metrics, reimbursement yield, denial rates, and net program margin.

Where competitors may have an advantage

Autonomous AI competitors provide an on-device instant-result narrative with some published validation.
Camera-only ecosystems can offer procurement flexibility and potentially lower costs depending on vendor quotes.

03Field reports

Availability of third-party review platform feedback (G2/Capterra/TrustRadius)

No Optain product listings or review corpora were found on G2, Capterra, or TrustRadius in the searches performed. This absence is common for early-stage medtech platforms that sell primarily to enterprise health systems.

Vendor-published testimonials (summary)

Optain’s site includes short, unattributed positive comments. These vendor-published statements lack attribution (name, organization, role), which limits their decision-usefulness. Paraphrased examples from vendor content: - A clinician noted the solution provides additional clinical information and increases confidence in eye health discussions. - A user reported the product was easy to use and that results were provided rapidly. - Another comment described the product as a clinical tool that supports quality-related discussions with patients.

Community/social discussions (negative/neutral)

Searches for Optain in community forums primarily returned results for an unrelated macOS application named “Optain.” No substantive Reddit or Hacker News feedback about Optain’s retinal screening platform was identified in the reviewed results.

Likely reasons buyers select Optain (inferred from vendor positioning)

Based on public messaging, buyers may choose Optain when they prioritize:

workflow integration and adoption (simplified capture, short training time claimed)
non-dilated imaging to reduce visit friction
rapid report turnaround with results returned to the EHR
a consolidated vendor for camera, grading, and integration services

Potential reasons for non-purchase or churn (hypotheses to validate)

Third-party review data is scarce; the following are risks that should be validated through reference calls and procurement: - EHR integration complexity or limitations beyond vendor claims - variable image quality or gradability in real-world primary care settings - turnaround time variability under high volume - total cost compared with autonomous AI or camera-plus-third-party-reading alternatives - referral network capacity, since increased detection requires downstream specialist care

Public case studies on Optain’s site

No detailed, quantified case study pages were identified in the reviewed sources beyond press releases and marketing summaries.

Vendor/PR metrics (require verification)

Acquisition materials included self-reported metrics for the acquired reading network and for Optain’s deployment footprint.

Critical evaluation: These figures are plausible for a large teleophthalmology network, but procurement should request cohort definitions (time period, screened definition), outcome definitions, and audited or peer-reviewed evidence when these metrics are used to justify ROI.

04Best fit

Company sizes

Best fit appears to be:

Mid-to-large provider organizations (multi-site systems)
Primary care groups with sufficient diabetes patient volume to justify program operations
Health plans or payors with population health budgets

Industries / verticals

Integrated delivery networks (IDNs)
Primary care groups (including value-based care organizations)
FQHCs and county health systems
Community screening and home-health operators

Roles and personas

Decision-makers:

VP Population Health, VP Clinical Operations
CMIO / Informatics leaders (EHR integration)
Ophthalmology service line leadership (referral pathways)
Quality leaders (HEDIS/Stars/HCC improvement)

End users:

Medical assistants and nurses capturing images
Primary care clinicians reviewing reports in the EHR
Care coordinators managing referrals

Pain points addressed

Low diabetic eye exam screening rates
Specialist access constraints and patient drop-off
Need for in-clinic screening without dilation

05The pitch

What the product does (objective value proposition)

Optain provides a combined medical device and software/clinical services platform for retinal screening in non-specialist settings (primary care, FQHCs, health systems, health plans, and community screening events). The vendor-described workflow is: 1) capture non-mydriatic retinal images using Optain’s imaging device or a compatible device (depending on region and configuration), 2) upload images securely, 3) return a clinical report—via AI algorithms in some regions and via teleophthalmology grading services in the US, 4) push results back into the EHR and quality dashboards. Optain frames retinal imaging as a source of information about ocular and systemic disease risk. The platform offers screening for diabetic retinopathy and other conditions, and, in certain regions outside the US, markets cardiovascular risk assessment derived from retinal images.

Target market and market positioning

**Target customers:** - Primary care groups and health systems running diabetes/quality-measure programs - FQHCs and county health systems aiming to close care gaps - Health plans and population health programs - Community screening and at-home care programs **Positioning:** - A product intended to integrate into frontline workflows, emphasizing short training time, non-mydriatic capture, and rapid report turnaround via teleophthalmology - An integrated offering combining hardware, software, and workflow integration support

Get a comprehensive analysis of Optain including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →